A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1070001
Abstract: Purpose To compare the pharmacokinetic (PK) bioequivalence (BE) and safety of a generic pegylated liposomal doxorubicin (PLD) formulation with the reference product Caelyx®. Methods A multicenter, single-dose, open-label, randomized, two-way crossover study was conducted in… read more here.
Keywords: doxorubicin; encapsulated doxorubicin; bioequivalence; bioequivalence safety ... See more keywords